OLA
BBH icon

Oliver Luxxe Assets’s VanEck Biotech ETF BBH Stock Holding History

Oliver Luxxe Assets’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,623
Closed -$1.57M – 92
2017
Q4 		$1.57M Buy
+12,623
New +$1.61M 0.96% 38

Other funds holding BBH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
MJRIC
Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return
BRM
Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

Oliver Luxxe Assets's BBH Position: Q1 2018 in Review

Oliver Luxxe Assets sold out of VanEck Biotech ETF (BBH) in Q1 2018, closing a stake of 12,623 shares — an estimated $1.57M sold.

Oliver Luxxe Assets first reported a position in BBH in Q4 2017 and held it in 1 quarter. The position peaked at $1.57M in Q4 2017. 82 funds tracked by Wall St. Rank hold BBH as of Q1 2018.

  • Oliver Luxxe Assets reported no remaining VanEck Biotech ETF position as of Q1 2018 after selling out during the quarter.
  • Oliver Luxxe Assets sold 12,623 VanEck Biotech ETF shares in Q1 2018, an estimated $1.57M.
  • Oliver Luxxe Assets first reported a position in VanEck Biotech ETF in Q4 2017 and held it in 1 quarter.
  • Oliver Luxxe Assets's VanEck Biotech ETF position peaked at $1.57M in Q4 2017.
  • 82 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2018.

Based on Oliver Luxxe Assets's 13F filing for Q1 2018, filed 17 Apr 2018.